Old and new antiepileptic drugs for the treatment of idiopathic generalized epilepsies

Current Clinical Pharmacology

Volumn 2, Issue 3, 2007, Pages 249-259

  Verrotti, Alberto ^a   Greco, Rita ^a   Giannuzzi, Raffaella ^a   Chiarelli, Francesco ^a   Latini, Giuseppe ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b Perrino Hospital of Azienda Ospedaliera Di Summa

Author keywords

Epilepsy; Epileptic patients; New antiepileptics; Old antiepileptics

Indexed keywords

ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLOBAZAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; LAMOTRIGINE; MACROLIDE; NORCLOBAZAM; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ABDOMINAL PAIN; ABSENCE; AGGRESSION; AGITATION; AGRANULOCYTOSIS; ANHIDROSIS; ANOREXIA; ANXIETY; APLASTIC ANEMIA; ASTHENIA; ATAXIA; BEHAVIOR DISORDER; BLOOD TOXICITY; BLURRED VISION; BRAIN DISEASE; CEREBELLUM ATROPHY; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG WITHDRAWAL; EPIGASTRIC PAIN; EUPHORIA; FATIGUE; FATTY ACID OXIDATION; FOOD; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; GINGIVA HYPERPLASIA; HAIR LOSS; HALLUCINATION; HAND TREMOR; HEADACHE; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HIRSUTISM; HUMAN; HYPERACTIVITY; HYPERAMMONEMIA; HYPERKINESIA; HYPERTHERMIA; HYPONATREMIA; IMPOTENCE; INSOMNIA; INSULIN RELEASE; IRRITABILITY; KIDNEY DYSFUNCTION; LETHARGY; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LUPUS LIKE SYNDROME; MEMORY DISORDER; MENTAL CONCENTRATION; METABOLIC ACIDOSIS; METABOLIC DISORDER; MONOTHERAPY; MUSCLE CRAMP; MYOCLONUS EPILEPSY; NAUSEA; NAUSEA AND VOMITING; NEPHROLITHIASIS; NERVOUSNESS; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OVARY POLYCYSTIC DISEASE; PAIN; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOTOPHOBIA; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STUPOR; SUICIDAL IDEATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICONVULSANTS; EPILEPSY, GENERALIZED; HUMANS; INFANT; INFANT, NEWBORN;

EID: 34948840400     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488407781668794     Document Type: Review

References (142)

1. Commission on Classification Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epileptic syndromes. Epilepsia 1989; 30: 389-99.
2. Malafosse A, Genton P, Hirsch E, Marescaux C, Broglin D, Bernasconi R, eds. Idiopathic generalised epilepsies. London: John Libbery & Company Ltd, 1994.
3. Duncan JS, Panayiotopoulos CP, eds. Typical absences and related epileptic syndromes. London: Churchill Communications Europe, 1995.
4. Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Paediatir Drugs 2001; 3: 379-403.
5. Engel J, Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: Report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001; 42: 796-803.
6. Panayiotopoulos CP. Idiopathic generalised epilepsies: A review and modern approach. Epilepsia 2005; 46(Suppl 9): 1-6.
7. A receptor function and pharmacology in epilepsy and status epilepticus. Curr Opin Pharmacol 2003; 3: 12-8.
8. Plouin P. Benign familial neonatal convulsions and benign idiopathic neonatal convulsions. In Engel J, jr., Pedley TA, eds. Epilepsy. A comprehensive textbook, Lippinoott-Raven, 1997, 2247-55.
9. Hirsch E, Saint-Martin A, Marescaux C. Benign familial neonatal convulsions: a model of idiophatic epilepsy. Rev Neurol 1999; 155: 463-7.
10. Plouin P, Anderson VE. Benign familial and non familial neonatal seizures. In Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, eds. Epileptic syndromes in infancy, childhood and adolescence (3rd edn), London: John Libbey & Co Ltd, 2002; 3-13.
11. Vidaurre JA, Ballaban-Gil KR, Plouin P, Moshe SL. Benign neonatal familiar seizures. In Gilman S, ed. Medlink Neurology. San Diego SA: Arbor Publishing Corp, 2004.
12. Engel J Jr. Classifications of the International League Against Epilepsy: time for reappraisal. Epilepsia 1998; 39: 1014-7.
13. Ronen GM, Penney S, Andrews W. The epidemiology of clinical neonatal seizures in Newfoundland: a population based study. J Pediatr 1999; 134: 71-5.
14. Ronen GM, Rosales TO, Connolly M, Anderson VE, Leppert M. Seizure characteristics in chromosome 20 benign familial neonatal convulsions. Neurology 1993; 43: 1355-60.
15. Ryan SG, Wiznitzer K Hollman C, et al. Benign familiar neonatal convulsions: evidence for clinical and genetic heterogeneity. Ann Neurol 1991; 29: 469-73.
16. de Falco FA, Majello L, Santangelo R, et al. Familial infantile myoclonic epilepsy: clinical features in a large kindred with autosomal recessive inheritance. Epilepsia 2001; 42: 1541-8.
17. Panayiotopoulos CP. Absence epilepsies. In Engel JJ, Pedley TA, eds. Epilepsy. A comprehensive Texbook, Philadelphia: Lippincott-Raven Publishers, 1997; 2327-46:
18. Loiseau P, Panayiotopoulos CP. Childhood absence epilepsy. In Gilman S, eds Medlink Neurology, San Diego SA: Arbor Publishing Corp, 2004.
19. Loiseau P, Duch B, Pedespan JM. Absence epilepsies. Epilepsia 1995; 36: 1182-7.
20. Wolf P. Juvenile absence epilepsy. In Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, eds. Epileptic syndromes in infancy, childhood and adolescence, London: John Libbery & Company, 1992; 307-12.
21. Obeid T. Clinical and genetic aspects of juvenile absence epilepsy. J Neurol 1994; 241: 487-91.
22. Panayiotopoulos CP, Giannakodimos S, Chroni E. Typical absences in adults. In Duncan JS, Panayiotopoulos CP, eds. Typical absences and related epileptic syndromes, London: Churchill Communications Europe, 1995; 289-99.
23. Oller L. Prospective study of the differences between the syndromes of infantile absence epilepsy and syndromes of juvenile absence epilepsy. Rev Neurol 1996; 24: 930-6.
24. Panayiotopoulos CP. Absence status epilepticus. In Gilman S. eds. Medlink Neurology, San Diego SA: Arbor Publishing Corp. 2004.
25. Agathonikou A, Panayiotopoulos CP, Giannakodimos S, Koutroumanidis M. Typical absence status in adults: diagnostic and syndromic considerations. Epilepsia 1998; 39: 1265-76.
26. Reutens DC, Berkovic SF. Idiopathic generalized epilepsy of adolescence: are the syndromes clinically distinct? Neurology 1995; 45: 1469-76.
27. Obeid T, Panayiotopoulos CP. Juvenile Myoclonic epilepsy: a study in Saudi Arabia. Epilepsia 1988; 29: 280-2.
28. Simonsen M, Mollgraard V, Lund M. A controlled clinical and electro-encephalographic study of myoclonic epilepsy. In: Janz D, Epileptology, Sttuttgart: Thieme 1976; 41-8.
29. Gelisse P, Genton P, Rayband C, Thomas P, Dravet C. Structural brain lesions do not influence the prognosis of juvenile myoclonic epilepsy. Acta Neurol Scand 2000; 102: 188-91.
30. Suzuki T, Ganesh S, Agarwala KL, et al. A novel gene in the chromosomal region for juvenile myoclonic epilepsy on 6p12 encodes a brain-specific lysosomal membrane protein. Biochem Biophys Res Commun 2001; 288: 626-36.
31. Koepp Mi, Duncan JS. Epilepsy. Curr Opin Neurol 2004; 17: 467-74.
32. Taylor I, Marini C, Johnson MR, Turner S, Berkovic SF, Scheffer IE. Juvenile Myoclonic epilepsy and idiopathic photosensitive occipital lobe epilepsy: is there overlap? Brain 2004; 127: 1878-86.
33. Thomas P, Genton P, Gèlisse P, Wolf P. Juvenile myoclonic epilepsy. In: Roger J, Bureau M, Dravet Ch, Genton P, Tassinari CA, Wolf P, editors. Epileptic syndromes in infancy, childhood and adolescences (4th edition). Montrouge; John Libbey Eurotext, 2005; 367-88.
34. Panayiotopoulos CP, Obeid T, Tahan AR. Juvenile Myoclonic epilepsy: a 5-year prospective study. Epilepsia 1994; 35: 285-96.
35. Janz D, Dumer M. Juvenile myoclonic epilepsy. In: Engel J, Pedley TA. Epilepsy. A comprehensive textbook, Lippincott-Raven, Philadelphia, 1997; 2389-400.
36. Jain S, Padma MV, Maheshwari MC. Occurrence of only myoclonic jerks in juvenile myoclonic epilepsy. Acts, Neurol Scand 1997; 95; 263-7.
37. Genton P, Gelisse P, Thomas P. Juvenile myoclonic epilepsy today: current definitions and limits. In: Schmitz B, Sander T. Juvenile myoclonic epilepsy: the jam syndrome. Wrightson Biomedical Publishing, Petersfield, 2000:11-32.
38. Panayiotopoulos CP, Obeid T, Waheed G. Absences in juvenile myoclonic epilepsy: a clinical and video-electroencephalographic study. Ann Neurol 1989; 25: 391-7.
39. Gelisse P. Genton P. Thomas P, Rey M, Samuelian JC, Dravet C. Clinical factors of drugs resistance in juvenile myoclonic; epilepsy. J Neurol Neurosurg Psychiatry 2001; 70: 240-3.
40. Loescher W. Effects of the antiepileptic drug valproate on metabolism and function inhibitory and excitatory amino acids in the brain. Neurochem Res 1993; 18: 485-502.
41. l Perucca E. Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714.
42. Dulac O, Stem D, Rey E, Perret A, Arthuis M. Sodium valproate monotherapy in childhood epilepsy. Brain Dev 1986; 8: 47-52.
43. Levy RH, Shen DD, Abbott FS, Riggs W, Hachad H. Valproic Acid. Chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perrucca E. eds. Antiepileptic, drugs, 5th eds. Philadelphia: Lippincott Williams & Wilkins, 2002; 3-22.
44. Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. Urinary excretion of valproate and some metabolites in chronically treated patients. Ther Drug Monit 1989; 11: 127-33.
45. Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 2003; 61: 23-6.
46. Tatum WO, Liporace J, Benbadis SR, Kaplan PW. Updates on the treatment of epilepsy in women. Arch Intern Med 2004; 164: 137-45.
47. Wyszynski DF, Holmes LB. The AED (antiepileptic; drug) pregnancy registry: a six year experience. Epilepsia 2004; 45 (Suppl) 3: 56.
48. Morrow JI, Russell A.TC, Irwin B, et al. The safety of antiepileptic drugs in pregnancy: results of the UK epilepsy and pregnancy register. Epilepsia 2004; 45 (Suppl) 3: 57.
49. Isojarvi JI, Tauboll E, Tapanainen JS, et al. On the association between valproate and polycystic ovary syndrome: A response and an alternative view. Epilepsia 2001; 42: 305-10.
50. Richens A, Davidson DLW, Cartlidge NEF, Faster D. A multicentre comparative trial of sodium valproate and carbarnazepine in adult onset epilepsy. Neurol Neurosurg Psychiatry 1994; 57: 682-7.
51. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazcpine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults: the Department of the Veteran Affairs Epilepsy Cooperative Study Group. N Engl J Med 1992; 327: 765-71.
52. Dinesen H, Gram L, Anderson T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70: 65-9.
53. Legarda SB, Booth MP, Fennell EB, et al. Altered cognitive functioning in children with idiopathic epilepsy receiving valproate monotherapy. J Child Neurol 1996; 11: 321-30.
54. Schmidt D. Adverse effects of valproate. Proceedings "Valproate Modern Perspectives", Satellite Symposium 15th Epilepsy International Symposium Washington, DC, Usa, Sept 1983. Epilepsia. 1984; 25 (Suppl), 44-9.
55. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000; 157: 818-20.
56. Forsythe I, Butler R, Berg I, et al. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neural 1991; 33: 524-34.
57. Beghi E, Bizzi A, Codegoni AM, et al. Valproate, carnitine metabolism, and biochemical indicators of liver function. Epilepsia 1990; 33: 346-52.
58. De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 1998; 39: 1216-25.
59. Guerrini R, Belmonte A, Canapicchi R, Casalini C, Perucca E. Reversible pseudoatrophy of the brain and mental deterioration associated with Valproate treatment. Epilepsia 1998b; 39: 27-32.
60. Verrotti A, Greco R, Morgese G, Chiarelli F. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int J Clin Lab Res 1999a; 29: 36-40.
61. Davis R, Peters DH, McTavish D. viaproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-172.
62. Mercke Y, Sheng H, Khan T, Lippmann S. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000; 12: 35-42.
63. Good CR, Feaster CS, Krecko VF. Tolerability of oral loading of divalproex sodium in child psychiatry inpatients. Child Adolesc Psychopharmacol 2001; 11: 53-7.
64. Asconape JJ, Peary JK, Dreifuss FE, Riela A, Mirza W. Valproate-associated pancreatitis. Epilepsia 1993; 34: 177-83.
65. Verrotti A, Greco R, Matera V, et al. Platelet count and function in children receiving sodium valproate. Pediatr Neurol 1999b; 21: 611-4.
66. Allarakhia IN, Garofalo EA, Komarynski MA, Robertson PL. Valproic, acid and thrombo-cytopenia in children: a case-controlled retrospective study. Pediatr Neurol 1996; 14: 303-7.
67. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22: 62-5.
68. Calleja S, Salas-Puig J, Ribacoba I, Lahoz CH. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate. Seizure 2001; 10: 424-7.
69. Macdonald RL, Kelly KM. Antiepileptic, drug mechanisms of action. Epilepsia 1993; 34(Suppl 5): 1-8
70. Genton P, Gelisse P, Thomas P, et al. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000; 55: 1106-9.
71. Gelisse P, Genton P, Kuate D, Presenti A, Baldy-Moulinier M, Crespel A. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45: 1282-8.
72. Talwar D, Arora MS, Sher PK. EEG changes and seizure exacerbation in young children treated with carbamazepine. Epilepsia 1994; 35: 1154-9.
73. Kochen S, Giagante B, Oddo S. Spike-and-wave complexes and seizure exacerbation caused by carbamazepine. Eur J Neural 2002; 9: 41-7.
74. Gansauer M, Alsaadi TM. Carbamazepine-induced seizures: a case report and review of the literature. Clin Electroencephalogr 2002; 33: 174-7.
75. Barzaghi N, Gatti G, Manni K et al. Comparative pharmacokinetics and pharmacodynamics of eterobarbital and phenobarbital in normal volunteers. Eur J Drug Metabol Pharmacokinet 1991; 16: 81-7.
76. Yukawa E, To H, Ohdo S, et al. Population based investigation of valproic acid relative clearance using nonlinear mixed effects modelling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol 1997; 37: 1160-7.
77. Taylor S, Tudur S, Williamson PR, Marson AG. Phenobarbital versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev 2001; CD002217.
78. de Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-13.
79. Benbadis SR, William O, Tatum WO, et al. Idiopathic generalized epilepsy and choice of antiepileptic drugs. Neurology 2003; 61: 1793-5.
80. Pellock JM. Treatment considerations: traditional antiepileptic drugs. Epilepsy Behav 2002; 3: 18-23.
81. Hamano SI, Mochizuki M, Monkawa T. Phenobarbital-induced atypical absence seizure in benign childhood epilepsy with centrotemporal spikes. Seizure 2002; 11: 201-4.
82. Yang MT, Lee WT, Chu LW, et al. Anti-epileptic drugs-induced de novo absence seizures. Brain Dev 2003; 25: 51-6.
83. Osorio I, Reed RC, Peltzer JN. Refractory idiopathic absence status epilepticus: a probable paradoxical effect of phenytoin and carbamazcpine. Epilepsia 2001; 41: 887-94.
84. Cocito L, Audenino D, Primavera A. Antiepileptic drugs may trigger absence status epilepticus. Epilepsia 1998; 39: 89.
85. Posner EB, Mohamed K, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2003; CD003032.
86. Glauser TA. Ethosuximide. In Shorvon S, Perucca E, Fish D, Dodson E, eds. The treatment of epilepsy (2nd edition), Oxford: Blackwell Publishing, 2004; 391-402.
87. Manning JP, Kichards DA, Leresche N, Crunelli V, Bowery NG. Cortical-area specific block of genetically determined absence seizures by ethosuximide. Neuroscience 2004; 123: 5-9.
88. Manning JP, Richards DA, Bowery NG. Pharmacology of absence epilepsy. Trends Pharmacol Sci 2003; 24: 542-9.
89. Strolin BM, Whornsley R, Nicolas JM, et al. Pharmacokinetics and metabolism of 14 C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol 2003; 59: 621-30.
90. A receptor subtypes. Nature 1999; 401: 796-800.
91. Bernus I, Dickinson RG, Hooper WD, et al. Anticonvulsant therapy in aged patients. Drug Aging 1997; 10: 278-89.
92. Bawden HN, Carnfield CS, Carnfield PR, et al. The cognitive and behavioural effects of clobazan and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. Epilepsy Res 1999; 33: 133-43.
93. Faught E. Clinical trials for treatment of primary generalized epilepsies. Epilepsia 2003; 44(Suppl 7): 44-50.
94. Montenegro MA, Cendes F, Noronha AL, et al. Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia 2001; 42: 539-42.
95. Leppik IE. Felbamate. In Shorvon S, Perrucca E, Fish D, Dodson E, eds. The treatment of epilepsy (2nd edition), Oxford: Blackwell Publishing, 2004; 403-9.
96. Bourgeois BF. Felbamate in the treatment of partial-onset seizures. Epilepsia 1994; 35(Suppl 5): 58-61.
97. Bartoli A, Guerrini R, Belmonte A, et al. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 1997; 19: 252-60.
98. Patsalos PN, Perucca E. Clinically important interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 6: 347-56.
99. Pisani F, Richcns A. Lamotrigine: adverse effects. In: Antiepileptic drugs, 5th eds. Levy RH, Mattson RH, Meldrum BS, Perucca E eds, Lippincott Williams & Wilkins adelphia, USA, 2002; 408-14.
100. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol 2000; 23: 160-3.
101. Biraben A, Allain H, Scarabin JM, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000; 55: 1758.
102. Carrazana EJ, Wheeler SD. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2001; 56: 1424-5.
103. Prasad A, Kuzniecky RI, Knowlton RC, et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2003; 60: 1100-5.
104. Grunewald RA, Salas PJ, Genton P, Panayiotopoulos CP. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2004; 61: 1328.
105. Martinez JF, Fountain NB. Frequency of myoclonic seizure exacerbation by lamotrigine in JME. Epilepsia 2003; 44(Suppl 9): 268.
106. Morris GL, Hammer AE, Kustra RP, Messenheimer JA. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav 2004; 5: 509-12.
107. de Haan GJ, Edelbrock P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokineties: a monotherapy study. Neurology 2004; 63: 571-3.
108. Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004; 62: 292-5.
109. Patsalos PN. Pharmacoldnetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85: 77-85.
110. Patsalos PN. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Rev Contemp Pharmacother 2004; 13: 1-168.
111. Lynch BA, Lambeng N, Nocka Y, et al. The synaptic vesicle protein SV2A is the binding site for tlie antiepileptic drug levetiracetam. Proc Nati Acad Sci USA 2004; 101: 9861-6.
112. Klitgaard H, Pitkanen A. Antiepileptogenesis neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord 2003; 5(Suppl 1): 9-16.
113. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 2001; 42(Suppl 4): 13-8.
114. Perucca E, Johannessen SI. The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? Epileptic Disord 2003; 5(Suppl 1): 17-26.
115. Herranz JL, Rufo-Campos M, Arteaga R. Effectiveness and tolerability of levetiracetam in 43 children and adolescents with epilepsy. Rev Neurol 2003; 37: 1005-8.
116. Tan MJ, Appleton RE. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure 2004; 13: 142-5.
117. Lagae L, Buyse G, Deconinck A, Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediatr Neurol 2003; 7: 123-8.
118. French J. Use of levetiracetam in special populations. Epilepsia 2001; 42(Suppl 4): 40-3.
119. Czapinski PP, Czapinska EM. The effectiveness of levetiracetam in drug-resistant juvenile myoclonic epilepsy. Epilepsia 2004; 45 (Suppl 3): 141.
120. La Neve A, Boero G, Specehio N, et al. Levetiracetam is effective in juvenile myoclonic epilepsy. Epilepsia 2004; 45(Suppl 3): 141.
121. Resor SR, Resor LD. Levetiracetam monotherapy in the treatment of convulsive seizures in juvenile myoclonic epilepsy. Presented at the 54th Annual Meeting of the American Academy of Neurology, April 13-20, Denver, CO, 2002.
122. Jongsma M, Janssen G, Engelsman M, et al. Promising results of levetiracetam in juvenile myoclonic epilepsy. Epilepsia 2002; 43(Suppl 8): 153.
123. Greenhill L, Betts T, Smith K. Effect of levetiracetam on resistant juvenile myoclonic epilepsy. Epilepsia 2002; 43(Suppl 7): 179.
124. Van Zandijcke M. Treatment of myoclonus. Acta Neurol Belg 2003; 103: 66-70.
125. Crest C, Dupont S, Le Guern E, et al. Levetiracetam in progressive myoclonic epilepsy: an,exploratory study in 9 patients. Neurology 2004; 62: 640-3.
126. Gallagher MJ, Eisenman LN, Brown KM, et al. Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy. Epilepsia 2004; 45: 90-1.
127. Krauss GL, Betts T, Abou-KhaM B, et al. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 2003; 12: 617-20.
128. Kumar SP, Smith PE. Levetiracetam as add-on therapy in generalised epilepsies. Seizure 2004; 13: 475-7.
129. Cavitt J, Privitera M. Levetimetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence. Arch Neurol 2004; 61: 1604-7.
130. Baeta E, Santana I, Castro G, et al. Cognitive effects of therapy with topiramate in patients with refractory partial epilepsy. Rev Neurol 2002; 34: 737-41.
131. Ormrod D, McClellan K. Topiramate: a review of its use in childhood epilepsy. Paediatr Drugs 2001; 3: 293-319.
132. Nieto BM. Characteristics and indications of topirumate. Rev Neurol 2002; 35(Suppl 1): 88-95.
133. Prasad A, Knowlton KC, Mendez M, Martin R, Kuzniecky R, Faueht E. A comparison of lamotrigine and topiramate in juvenile myoclonic epilepsy. Epilepsia 2002; 43(Suppl 7): 198-9.
134. Prasad A, Kuzniecky RI, Knowlton RC, et al. Evolving antiepileptic drug treatraent in juvenile myoclonic epilepsy. Arch Neurol 2003; 60: 1100-5.
135. Cross JH. Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure 2002; 11: 406-10.
136. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000; 41: 1167-78.
137. Kockelmann E, Elger CE, Helmstaedtcr C. Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res 2003; 54: 171-8.
138. Leppik IE. Three new drugs for epilepsy: levetiracetam, oxacarbazepine and zonisamide. J Child Neurol 2002; 17(Suppl 1): 53-7.
139. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant, partial epilepsy. Cochrane Database Syst Rev 2002; CD004416.
140. Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neural 2002; 17: 87-96.
141. Sullivan JE, Dlugos DJ. Idiopathic Generalized Epilepsy. Curr. Treat Options Neurol 2004; 6: 231-42.
142. Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Res 2005; 64: 31-4.